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Abstract
Background: Astragali Radix has been used widely for the treatment of cardiovascular and cerebrovascular
diseases, and to enhance endurance and stamina in traditional Chinese medicine (TCM) for over 2000 years. The
polysaccharide constituents of Astragali Radix (ARP) are considered as one of the major constituents contributing
to the multiple pharmacological effects of this medicinal plant. The purpose of the study is to evaluate the vascular
regenerative activities of ARPs in a chemically-induced blood vessel loss model in zebrafish.
Methods: Blood vessel loss was induced in both Tg(fli-1a:EGFP)y1 and Tg(fli-1a:nEGFP)y7 embryos by
administration of 300 nM VEGFR tyrosine kinase inhibitor II (VRI) for 3 h at 24 hpf (hour post-fertilization). Then, the
blood vessel damaged zebrafish were treated with ARPs for 21 h and 45 h after VRI withdrawal. Morphological
changes in intersegmental vessels (ISVs) of zebrafish larvae were observed under the fluorescence microscope and
measured quantitatively. The rescue effect of ARPs in the zebrafish models was validated by measuring the relative
mRNA expressions of Kdrl, Kdr and Flt-1 using real-time PCR.
Results: Two polysaccharide fractions, P4 (50000 D < molecular weight & diameter < 0.1 μm) and P5 (molecular
diameter > 0.1 μm), isolated from Astragali Radix by ultrafiltration, produced a significant and dose-dependent
recovery in VRI-induced blood vessel loss in zebrafish. Furthermore, the down-regulation of Flk-1 and Flt-1 mRNA
expression induced by VRI was reversed by treatment with P4.
Conclusion: The present study demonstrates that P4 isolated from Astragali Radix reduces VRI-induced blood
vessel loss in zebrafish. These findings support the hypothesis that polysaccharides are one of the active
constituents in Astragali Radix, contributing to its beneficial effect on treatment of diseases associated with a
deficiency in angiogenesis.
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Background
Angiogenesis plays an important role in a wide range of
physiological processes, such as wound healing and fetal
development. However, many diseases such as cancer,
chronic inflammatory disease, diabetic retinopathy,
macular degeneration and cardiovascular disorders are
associated with dysregulation of angiogenesis, in which
blood vessel formation is either excessive or insufficient.
Improvement of endothelial cell function and the
enhancement of angiogenesis after critical cardiac and
skeletal muscle ischemia is critical, as neovascularization
of ischemic tissues may be sufficient to preserve tissue
integrity and/or function, and thus is therapeutic. Poly-
saccharides are naturally occurring polymeric carbohy-
drate structures formed of repeating units of mono- or
di-saccharides joined together by glycosidic bonds. This
group of natural compounds are present in many tradi-
tional Chinese herbs and are reported to have both pro-
angiogenic [1,2] and anti-angiogenic [3-6] activities. Our
previous discovery of a pro-angiogenic herb called
Angelica sinesis by zebrafish assay leading to develop-
ment of a wound healing formulation for diabetic foot
ulcer patients [7,8].
Astragali Radix, the dried root of Astragalus membra-
naceus (Fisch) Bge. or Astragalus mongholicus Bge.
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any medium, provided the original work is properly cited.(Fabaceae), has been used in traditional Chinese medi-
cine (TCM) for centuries to enhance the immune sys-
tem, increase stamina and endurance, and to treat
cerebrovascular and cardiovascular diseases [9]. In
China, the herb is commonly known as “Huangqi”,a n d
was first recorded in Shen Nong’s Materia Medica about
two thousand years ago. The primary constituents of
Astragali Radix include polysaccharides, triterpene sapo-
nins, flavonoids, amino acids and trace elements [10,11].
Clinically, Astragali Radix is used as either a single herb
or in a TCM formula in combination with other herbal
medicines. As a single herb, it stimulates the formation
of capillaries in the chick embryo chorioallantoic mem-
brane, and induces the proliferation of human umbilical
vein endothelial cells (HUVEC) [12,13].
In our previous study, an extract of Astragali Radix
containing flavonoids, saponins and polysaccharides sti-
mulated angiogenesis involving the VEGF-KDR/Flk and
PI3K-Akt-eNOS pathways [14]. Calycosin, one of the
major isoflavones in Astragali Radix, was found to pro-
mote angiogenesis in normal zebrafish [15], whereas
astragaloside IV reduced chemically-induced blood ves-
sel loss [16]. However, there are no systematic and in-
depth studies investigating the angiogenesis activities of
fractionated polysaccharides from Astragali Radix
(ARPs).
New opportunities for in vivo natural product discov-
ery have arisen through the recent emergence of zebra-
fish as an effective model system for the identification of
disease-relevant genes and bioactive small molecules
[17]. The primary advantages of zebrafish for drug dis-
covery include their high genetic, physiologic, and phar-
macologic similarity with humans [17,18]. In particular,
in vivo screening of the angiogenic effects of ARP in
zebrafish provides a more physiologically relevant result
compared to in vitro screening because polysaccharides
are often subjected to modification by the gastrointest-
inal tract and drug metabolism systems in vivo.A l s o ,
our recent studies suggest a high similarity of phase I
and phase II drug metabolism systems between zebrafish
and mammals [19,20]. In the present study, we have
investigated the vascular effects of fractionated ARPs
based on molecular size in zebrafish angiogenesis assays.
Materials and methods
Ethics statement
All animal experiments were conducted according to the
ethical guidelines of ICMS, University of Macau and the
protocol was approved by ICMS, University of Macau
prior to the initiation of the experiments.
Chemicals and reagents
Dimethyl sulfoxide (DMSO) was purchased from Sigma,
S t .L o u i s ,U S A .V E G F Rt y r o s i n ek i n a s ei n h i b i t o rI I
( V T K I ,V R I )w a sp u r c h a s e df r o mC a l b i o c h e mC o m -
pany/EMD Chemicals Inc (Cat. No. 676481) and was
dissolved in DMSO to form a 1 mg/mL solution. Puri-
fied water was prepared with a Milli-Q purification sys-
tem from Millipore (Milford, USA).
Preparation and analysis of ARP fractions
The dry roots of Astragali Radix (3,000 g) were
extracted twice with 30 L distilled water at 80°C for 2
hours, and then filtered to remove impurities. The aqu-
eous extract was concentrated and applied to an
HPD600 macroporous resin column for further separa-
tion. The column was eluted with 10 L of ethanol and
the aqueous portion was collected by eluting with 12 L
of water, and then precipitated by the addition of three
volumes of 80% (v/v) ethanol, and the precipitate was
left to stand overnight. The resultant precipitate was
collected by centrifugation, and then dried under
vacuum. This dried polysaccharide extract was re-dis-
solved in distilled water and treated with Sevag reagent
(1:4 n-butanol:chloroform, v/v, 3000 mL × 5) to remove
proteins. The deproteined polysaccharide fraction was
further fractionated using ultrafiltration with a series of
commercial ultrafiltration membranes (size 10 K, 30 K,
50 K and 0.1 μm, Millipore, USA), according to the
molecular weight (MW) and diameter (DM) of the tar-
get polysaccharide fraction.
The total sugar content was determined by a modified
p h e n o l / s u l f u r i ca c i dm e t h o d[ 2 1 ]a te a c hs t e p ,a n dt h e
yields of each polysaccharide fraction were calculated.
Furthermore, the number-average molecular weight
(Mn) and the weight-average molecular weight (Mw) of
the active ARP fractions with higher efficacy and
potency (P4) were determined by gel permeation chro-
matography (GPC). The uronic acid content of P4 was
also determined using the hydroxydiphenyl method as
previously described [22]. The monosaccharide units of
P4 were analyzed by gas chromatography (GC), and sev-
eral types of monosaccharides were used as reference
standards.
Maintenance of zebrafish and its embryos
The zebrafish strains, including Tg(fli-1a:EGFP)y1 and
Tg(fli-1a:nEGFP)y7, were maintained as previously
described (Westerfield et al. 1995).
Zebrafish embryo collection and drug treatment
Zebrafish embryos were generated by natural pair-wise
mating (3-12 months old) and were raised at 28.5°C in
embryo medium. Healthy, hatched zebrafish were picked
out at 24 hour post-fertilization (hpf) and distributed
into a 12-well microplate (15 embryos per well). They
were pretreated with 300 nM tyrosine kinase inhibitor
II, one of the VEGF receptor inhibitors (VRI), for 3 h.
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either 0.1% DMSO (v/v) embryo medium, or increasing
concentrations of each of the five ARP fractions for 45
h. The embryos receiving embryo medium only served
as a vehicle control. The media of all treatment groups
were refreshed every 24 h. Each experiment was
repeated at least three times.
Morphological observation of zebrafish
At 48 hpf and 72 hpf, zebrafish were removed from
microplates and observed for viability and gross mor-
phological changes under a fluorescence microscope
(Olympus IX81 Motorized Inverted Microscope, Japan)
equipped with a digital camera (DP controller, Soft Ima-
ging System, Olympus). Images were analyzed with
Axiovision 4.2 and Adobe Photoshop 7.0.
Assessment of vascular changes
24 hpf Tg(fli-1a:EGFP)y1 zebrafish embryos were pre-
treated with VRI for 3 h. Then after treatments of ARPs
for 21 h and 45 h, intersegmental vessels (ISVs) were
assessed for pro-angiogenesis activity of ARPs. In the
vehicle control group, ISVs can be seen sprouting and
elongating dorsally up from the dorsal aorta (DA), and
the posterior cardinal vein (PCV) below, to form a right
and left pair of dorsal longitudinal anastamotic vessels
(DLAVs) by 1.5 dpf [23]. In the vehicle control group,
ISVs observed sprouting and elongating from DA (and
CA) or PCV to DLAV were defined as intactness. In
VRI treatment groups (including the VRI-only treatment
group and the ARP treatment groups), some of the ISVs
observed sprouting from DA or PCV, but not forming a
complete ISV, were defined as a defective. The integrity
of twenty ISVs near the anus (ten ISVs in front of the
anus and ten ISVs after the anus) in each individual zeb-
rafish was measured. The percentage recovery was cal-
culated as the total length of the selected ISVs in the
treatment group over the total length of the selected
ISVs in the vehicle control group. For example: A 100%
percentage recovery indicated completed recovery of
ISVs in the treatment group the same as that in the
vehicle control group, whereas the VRI-only treatment
group showing complete inhibition of ISVs was set as
0% percentage recovery. Twenty ISVs near the anus (10
ISVs in front of the anus and 10 ISVs after the anus) in
each embryo were measured for total length. At least 10
larvae per group, over a series of 3 independent experi-
ments, were evaluated. Percentage recovery is defined as
the total length of the selected ISVs in the treatment
group over the total length of the selected ISVs in the
vehicle control group. In addition, the total number of
endothelial cells in the ISVs of Tg(fli-1a:nEGFP)y7 zeb-
rafish larvae were assessed by counting directly the
number of nuclei of GFP-positive endothelial cells
present in the twenty selected ISVs. Each green light
point represents one endothelial cell (GFP+). Data are
presented as the mean ± SD (n = 3),* P < 0.05, # P <
0.001.
Total RNA extraction, reverse transcription, and real-time
PCR
The zebrafish embryos were treated at 24 hpf as
described above. At 48 hpf, total RNA was extracted
from 30 zebrafish embryos of each treatment group,
using the RNeasy Mini Kit (Qiagen, USA) in accordance
with the manufacturer’s instructions. RNA was reverse
transcribed to single-strand cDNA using SuperScriptTM
III First-Strand Synthesis System for RT-PCR (Invitro-
genTM, USA), followed by real-time PCR using the
TaqManH Universal PCR Master Mix, and 250 nM cus-
tom TaqMan primers for zebrafish Kdrl, Kdr and Flt1
(Applied Biosystems, USA) in the ABI 7500 Real-Time
PCR System (Applied Biosystems). The expression of
Kdrl, Kdr and Flt1 was normalized to the amount of
bactin1, using the relative quantification method
described by the manufacturer.
The zebrafish bactin1 primers were 5’-CAAGATTC-
CATACCCAGGAAGGA- 3’ (F) and 5’-CAAGATTC-
CATACCCAGGAAGGA- 3’ (R) (Applied Biosystems,
USA).
The zebrafish Kdrl (Flk1A) primers were 5’- GACCA-
TAAAACAAGTGAGGCAGAAG- 3’ (F) and 5’-
CTCCTGGTTTGACAGAGCGATA- 3’ (R) (Applied
Biosystems, USA).
The zebrafish Kdr (Flk1B) primers were 5’-C A A G -
TAACTCGTTTTCTCAACCTAAGC- 3’ (F) and 5’-GG-
TCTGCTACACAACGCATTATAAC- 3’ (R) (Applied
Biosystems, USA).
The zebrafish FLT1 primers were 5’-AACTCACA-
GACCAGTGAACAAGATC- 3’ (F) and 5’-GCCCTGT-
AACGTGTGCACTAAA- 3’ (R) (Applied Biosystems,
USA).
Results
Preparation of ARP fractions
Five ARP fractions were prepared by extraction, isola-
tion, deproteination and ultrafiltration: P1 (MW <
10,000 D, 15 g), P2 (10,000 D < MW < 30,000 D, 25.2
g), P3 (30,000 D < MW < 50,000 D, 55.3 g), P4 (50,000
D<M W&D M<0 . 1μm, 75.5 g) and P5 (DM > 0.1
μm, 156 g). The total sugar content of each polysacchar-
ide fraction was: P1, 35.9%; P2, 36.2%; P3, 42.4%; P4,
42.9%; P5, 51.1%. The yield of each fraction was: P1,
0.5%; P2, 0.84%; P3, 1.84%; P4, 2.52%; P5, 5.12% (Table
1). The number-average molecular weight (Mn) and
weight-average molecular weight (Mw) of P4 was 6.46 ×
10
5 D and 1.61 × 106 D (see Additional File 1). The
uronic acid content of P4 was determined to be 26.9%.
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monosaccharides of P4 consisted of D-glucose, D-galac-
tose and D-glucuronic acid (see Additional File 2).
ARP fractions rescue VRI-induced blood vessel loss in
zebrafish
VEGFR tyrosine kinase inhibitor II (VRI), a pyridinyl-
anthranilamide compound that displays antiangiogenic
properties, strongly inhibits the kinase activities of both
VEGF receptor 1 and 2. The 27 hpf zebrafish embryos
pre-treated with 300 nM of VRI for 3 h were then
washed and placed in Milli Q water and incubated for
another 45 h. Treatment of the zebrafish with VRI
induces significant blood vessel loss in ISV (interseg-
mental vessels) and DLAV (dorsal longitudinal anasto-
motic vessels) (Figure 1A-A’ and Figure 1B-B’). After
incubating the VRI-pretreated embryos with P4 (30 and
100 μg/ml) (Figure 1F-H’) and P5 (100 and 300 μg/ml)
(Figure 1I-K’), respectively, for 21 h and 45 h, the VRI-
induced blood vessel loss in the ISV and DLAV regions
of the zebrafish was significantly reduced.
Quantitative analysis confirmed a significant (P <0 . 0 5
and P < 0.001, respectively) dose-dependent effect of P4
and P5 on the percentage recovery (the total length of
the selected ISVs in treatment group over the total
length of the selected ISVs in the vehicle control group)
of blood vessel loss in zebrafish as compared with the
control group (Figure 2). Meanwhile, there was no sig-
nificantly observable change in blood vessels in P1, P2
and P3 treatment groups at their maximum non-toxic
concentrations of 300 μg/ml, 100 μg/ml and 300 μg/ml,
respectively (Figure 1C-E’), compared with VRI-only
treatment group.
Moreover, Tg(fli-1a:nEGFP)y7 zebrafish were used to
confirm the angiogenic effects of different fractions of
ARP. Tg(fli-1a:nEGFP)y7 fish were engineered similarly
to Tg(fli-1a:EGFP)y1, with the exception that the Tg(fli-
1a:nEGFP)y7 harbor nuclear-localized GFP expression,
permitting real time in vivo analysis of individual
endothelial cells [24]. Compared with Tg(fli-1a:EGFP)y1
zebrafish that were used to evaluate the integrity of
blood vessels, Tg(fli-1a:nEGFP)y7 zebrafish were used to
measure the number of endothelial cells. The results
showed that after incubating with 0.1% DMSO (v/v)
embryo medium for 21 h and 45 h, the number of zeb-
rafish larvae endothelial cells in the ISV and DLAV
regions decreased dramatically following 0.3 μMV R I
pre-treatment for 3 h (Figure 3B-B’), compared to the
vehicle control (Figure 3A-A’). Similar to the results
with Tg(fli-1a:EGFP)y1 (Figure 1), this VRI-induced
blood vessel cell decrease was partially reduced after
treatment with P4 (30 and 100 μg/ml) (Figure 3G-H’)
and P5 (100 and 300 μg/ml) (Figure 3I-K’)f o r2 1ha n d
45 h. Quantitative analysis indicated that treatment of
Table 1 Description of ARPs extracted from Radix Astragali
P1 P2 P3 P4 P5
molecular weight (D) and
diameter range (μm)
molecular
weight < 10000
10000 < molecular
weight < 30000
30000 < molecular
weight < 50000
50000 < molecular weight
&diameter < 0.1
diameter
> 0.1
total sugar content (%) 35.9 36.2 42.4 42.9 51.1
yield (%) 0.5 0.8 1.8 2.5 5.1
maximum non-toxic dosage
(μg/ml)
300.0 100.0 300.0 100.0 300.0
Figure 1 The effect of ARPs on VRI-induced blood vessel loss
in Tg(fli-1a:EGFP)y1 zebrafish (result of morphological
observation). White arrows indicate DLAV, ISV and DA of zebrafish.
Scale bar = 500 μm. (A-A’) Control group: 24 hpf embryos were
treated with 0.1% DMSO for 24 h and 48 h. 24 hpf embryos were
treated with VRI (300 nM) at for 3 h. After that, the VRI was washed
out and replaced with 0.1% DMSO (v/v) embryo medium (B-B’)o r
300 μg/ml P1 (C-C’), 100 μg/ml P2 (D-D’), 300 μg/ml P3 (E-E’), 10
μg/ml (F-F’), 30 μg/ml (G-G’) and 100 μg/ml (H-H’) P4, 30 μg/ml (I-I’),
100 μg/ml (J-J’) and 300 μg/ml (K-K’) P5 for 24 h.
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a n dP 5( 1 0 0a n d3 0 0μg/ml) significantly (P <0 . 0 1a n d
P < 0.001) increased the number of endothelial cells
(Figure 4) throughout the ISV region than the VRI-only
treatment group. P1 (300 μg/ml), P2 (100 μg/ml) and P3
(300 μg/ml) did not show significant observable rescue
effects on VRI-pretreated zebrafish larvae (Figure 3C-E’).
Since P4 exhibited higher potency and efficacy than P5
on the recovery of blood vessel loss in both Tg(fli-1a:
EGFP)y1 and Tg(fli-1a:nEGFP)y7 zebrafish lines, P4 was
selected for further mechanistic studies.
P4 reverses the VRI induced down regulation of flk-1 and
flt-1 mRNA expression
In order to confirm the vascular phenotypic effects of P4
observed in Figure 1, 2, 3, 4, total RNAs from different
groups of zebrafish pre-treated with VRI (0.3 μM) for 3
h, and then treated with different concentrations of P4
(10, 30 and 100 μg/ml) after VRI withdrawal, were iso-
lated and reverse transcribed to cDNA, and relative
mRNA expressions of Kdrl, Kdr and Flt-1 were deter-
mined, using real-time PCR. Vascular endothelial growth
factor receptor 1 (VEGFR1) is a protein that in zebrafish
is encoded by the FLT1 gene [25]. Its tyrosine protein
kinase activity is important for the control of cell prolif-
eration and differentiation. VEGFR2 (fetal liver kinase,
also known as KDR and Flk-1) has a higher affinity for
VEGF and is a major transducer of the VEGF signal in
endothelial cells [26,27]. Figure 7 represents the gene
expression levels (data expressed in a log2 scale) of three
key VEGFRs in 48 hpf zebrafish larvae that were pre-trea-
ted with 0.3 μM VRI for 3 h and then treated with P4 (10,
30, and 100 μg/ml) for 21 h after VRI withdrawal. P4
caused a significant increase in mRNA expression of Kdrl
(2.31-fold at 10 μg/ml, P < 0.001; 2.25-fold at 30 μg/ml, P
< 0.001; 2.58-fold at 30 μg/ml, P < 0.001), Kdr (2.67-fold
at 10 μg/ml, P < 0.001; 2.71-fold at 30 μg/ml, P <0 . 0 0 1 ;
2.85-fold at 100 μg/ml, P < 0.001) and Flt1 (1.77-fold at
10 μg/ml, P < 0.001; 1.63-fold at 30 μg/ml, P < 0.001;
1 . 9 6 - f o l da t1 0 0μg/ml, P <0 . 0 0 1 ) .T h u s ,t h e s er e s u l t s
suggest that P4 reversed the down-regulation of the
expression of several key angiogenesis genes involved in
VRI-induced blood vessel loss in zebrafish.
Discussion
Astragali Radix has been used as a single herb, or in
combination with other Chinese herbal medicines, for
Figure 3 The effect of ARPs on VRI-induced blood vessel loss
in Tg(fli-1a:nEGFP)y7 zebrafish (result of morphological
observation). White arrows indicate DLAV, ISV and DA of zebrafish.
Scale bar = 500 μm. (A-A’) Control: embryos treated with 0.1%
DMSO at 24 hpf for 24 h and 48 h. 24 hpf embryos treated with VRI
(300 nM) for 3 h. After that, the VRI was washed out and replaced
with 0.1% DMSO (v/v) embryo medium (B-B’) or 300 μg/ml P1 (C-
C’), 100 μg/ml P2 (D-D’), 300 μg/ml P3 (E-E’), 10 μg/ml (F-F’), 30 μg/
ml (G-G’) and 100 μg/ml (H-H’) P4, 30 μg/ml (I-I’), 100 μg/ml (J-J’)
and 300 μg/ml (K-K’) P5 for 24 h.
Figure 2 Effects of ARPs on VRI-induced blood vessel loss in
Tg(fli-1a:EGFP)y1 zebrafish (result of statistical analysis).
Percentage recovery (the total length of the selected ISVs in the
treatment group over the total length of the selected ISVs in the
vehicle control group) of each ISV of Tg(fli-1a:EGFP)y1 zebrafish
were calculated. Data are plotted as the mean ± SD, (n = 3), * P <
0.05, # P < 0.001 vs the VRI-only treatment group.
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stamina and endurance for thousands of years, which
prompted us to investigate the vascular protective
effects of ARPs from Astragali Radix. In the present
study, ARPs were isolated by ultrafiltration according to
different molecular weight ranges, and evaluating their
pro-angiogenesis effects using the live zebrafish angio-
genesis assays.
The results demonstrated that the Astragali Radix
polysaccharide fraction P4 (ranging from MW > 50,000
D and DM < 0.1 μm) and P5 (range: DM > 0.1 μm)
reduced VRI-induced blood vessel loss in zebrafish
models. Both the percentage recovery and the number
of endothelial cells of ISVs increased significantly fol-
lowing treatments with P4 and P5 in both the transgenic
Tg(fli-1a:EGFP)y1 and Tg(fli-1a:nEGFP)y7 zebrafish
models as compared with the VRI-only treatment group.
These findings indicate that P4 and P5 possess pro-
angiogenic activity. Compared to P5, the ARP fraction
P4 exhibited higher potency and efficacy.
The results also demonstrated that P4-treatments
induced phenotypic change in VRI-induced blood vessel
loss in the zebrafish model that were well validated by
recovery of the mRNA expressions of a few key gene
makers selected from angiogenesis signaling pathways.
VEGF, also known as vascular permeability factor (VPF),
was originally described as a potent angiogenic factor as
well as an essential growth factor for vascular endothe-
lial cells [28]. The formation of new blood vessels is
orchestrated by a variety of different proteins, including
cell adhesion molecules, extracellular matric compo-
nents and VEGFRs. Gene targeting experiments have
provided insights into the functions of VEGFRs [29,30].
Although inactivation of each individual VEGFR can
cause embryonic lethality atm i d - g e s t a t i o n ,t h e yh a v e
different functionality [31,32]. VEGFR2 is the receptor
that initiates the main signaling pathways activated by
VEGF. While the main function of VEGFR1 appears to
be in regulating the binding between VEGF and
VEGFR2 [33]. In this investigation, the results of real-
time PCR illustrate that different concentrations (10, 30
and 100 μg/ml) of P4 reversed VRI-induced down-regu-
lation of the expression of Kdrl, Kdr and Flt1 in the zeb-
rafish model. These data confirmed the predominant
involvement of these angiogenesis-specific targets in
P4’s rescue effect at ISVs in VRI-induced blood vessel
loss in zebrafish, and further supported the hypothesis
that these clear phenotypic changes were the result of
the recovery of angiogenesis deficiency.
Angiogenesis deficiencies are associated with numer-
ous human cardiovascular and cerebrovascular diseases
(e.g., ischemic cardiac and cerebral problems). The work
presented here shows that VRI-induced blood vessel
loss in zebrafish in vivo mimics angiogenesis deficiencies
associated with human disease conditions. Our in vivo
data suggests that P4 exerted a rescue effect only in a
damaged blood vessel disease model rather than in
Figure 4 Effects of ARPs on VRI-induced blood vessel loss in
Tg(fli-1a:nEGFP)y7 zebrafish (result of statistical analysis).
Numbers of endothelial cells in ISVs of Tg(fli-1a:nEGFP)y7 zebrafish
embryos were assessed by direct counting of the total number of
green light points within the twenty selected ISVs. Each green light
point represents one endothelial cell (GFP+). Data are plotted as the
mean ± SD, (n = 3), * P < 0.05, # P < 0.001 vs the VRI-only
treatment group.
Figure 5 Gene expression of P4 treated zebrafish.D a t aa r e
expressed as the mean ± SD, (n = 3), * P < 0.05, # P < 0.001 vs the
VRI-only treatment group.
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gests that P4 may be a novel therapy for the restoration
of angiogenesis deficiencies under pathophysiological
conditions. In summary, these data suggest that P4
exerts its angiogenic effects by rescuing damaged blood
vessels in zebrafish. They also indicate that ARPs are a
major group of active constituents in Astragali Radix.
Conclusion
In conclusion, this present study provides evidence sup-
porting the hypothesis that P4, a polysaccharide fraction
(50000 D < MW and DM < 0.1 μm) isolated from
Astragali Radix partially restores chemical-induced
blood vessel loss in the zebrafish model. Since polysac-
charides isolated from natural products usually undergo
the enzymatic breakdown of the sugar moiety in the
cells of the gastrointestinal mucosa, or by enzymes
secreted by the colon flora, to become active metabolites
after oral consumption by humans, the study of the
bioactivity of the polysaccharides required the develop-
ment of an in vivo assay equipped with mammalian-
equivalent drug metabolism systems. Recent studies sug-
gest that drug screening in zebrafish shows a good cor-
relation with clinical observations, and support its
potential as a model for pharmacological assessment of
small molecules, this is the first study to prove the con-
cept of screening the bioactivity of polysaccharides in
live zebrafish, whose drug metabolism systems were
shown recently to have a high degree of functional simi-
larity to that of mammals. Our findings also provide
insight into the important role of polysaccharides in the
effects of Astragali Radix for the treatment of various
pathological conditions associated with deficient angio-
genesis, such as ageing, stroke, ulcers and cardiovascular
diseases.
Additional material
Additional file 1: GPC chromatogram of polysaccharides in P4.Ai s
the major polysaccharide peak in P4: retention time, 10.9 min; number-
average molecular weight, 6.46 × 10
5; Weight-average molecular weight,
1.61 × 10
6; peak width, 2.49 min. Other peaks are monosaccharide peaks,
solvent peak and other impurities.
Additional file 2: GC-MS chromatogram of acetylated-
monosaccharide constituents in P4. A (retention time 12.10 min) is the
peak of internal standard (IS) inositol. B (retention time 12.68 min) is
acetylated-glucuronic acid. C (retention time 12.77 min) is sorbitol
hexaacetate. D (retention time 13.06 min) is galactose pentaacetate.
Abbreviations
Dpf: day(s) post fertilization; hpf: hour(s) post fertilization; D: Dalton; ARP:
Astragali Radix polysaccharide; DMSO: Dimethyl Sulfoxide; VTKI (VRI): VEGFR
tyrosine kinase inhibitor II; MW: Molecular Weight; Mn: number-average
molecular weight; Mw: weight-average molecular weight; GPC: Gel
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